Table 1.
Main characteristics of all studies included in the meta-analysis for overall survival.
| First author (pub year) | Patients Ki-67or MIB1 ± (total) | Median FU (mos) | Antibody | test method | Threshold (chosen by) | HR (95% CI) |
|---|---|---|---|---|---|---|
| Avall-Lundqvist EH (1997) | 109 | 82 (mean) | MIB-1 | IHC | 50%(PI) | 0.98 (0.84–1.14) |
| Bahnassy AA (2007) | 43 | NR | MIB-1 | IHC | 1%(PI) | 1.53 (1.03–20.7) |
| Dellas A (1997) | 76 | NR | MIB-1 | IHC | 34% (LI) | 1.04 (0.48–2.24) |
| Ho DM (2000) | 97 | 83.4 (mean) | MIB-1 | IHC | 55%(LI) | 3.62 (1.3–10.09) |
| Kuniyuki O (1996) | 186 | 60 | Anti-MIB-1 | IHC | 43% (PI) | 0.86 (0.49–1.52) |
| Klimek M (2011) | 122 | 5y | Anti-Ki-67 | IHC | 52% (PI) | 2.28 (1.27–4.11) |
| Oka K (2000) | 75 | NR | Anti-MIB-1 | IHC | 40% (PI) | 3.4 (0.53–22.15) |
| Shiohara S 1 (2005) | 103 | 65.1 (mean) | Anti-Ki-67 | IHC | 50% (PI) | 1.57 (0.53–4.66) |
| Shiohara S 2 (2005) | 103 | 65.1 (mean) | Anti-Ki-67 | IHC | 50% (PI) | 1.44 (0.32–6.39) |
| Sultana H (2003) | 30 | 5y | Anti-Ki-67 | IHC | 33% (LI) | 0.46 (0.04–5.99) |
| Suzuki M (2000) | 67 | 78 | Anti-MIB-1 | IHC | 26.4% (PI) | 0.49 (0.15–2.53) |
| Yang M (2014) | 180 | 64 (mean) | Anti-Ki-67 | IHC | 10% (PI) | 3.80 (1.80–4.70) |
| Zhang T (2012) | 40 | NR | Anti-Ki-67 | IHC | 34.62% (PI) | 3.44 (0.7–18.34) |
| Zhang T (2012) | 48 | NR | Anti-Ki-67 | IHC | 32.74% (PI) | 3.04 (0.73–13.26) |
FU – follow-up; HR – hazard ratio; CI – confidence interval; N+ – node-positive; NR – not reported + – positive; ‘−’ – negative; y – years; PI – proliferation index; LI – labeling index.